Q-omics provides the consensus-scored TEK profile across patient tissues and cancer cell-line models. TEK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TEK is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TEK RNA expression shows 22,857 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where TEK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEK survival associations across molecular data types. TEK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEK RNA expression–survival associations across cancer types. High TEK expression shows unfavorable associations in BLCA, KIRP and MESO, but favorable associations in KIRC, HNSC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TEK RNA expression.
This table summarizes TEK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TEK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEK shows lower tumor expression in KIRC, KICH, KIRP, LUAD, LUSC and COAD. The KIRC box plot shows higher TEK RNA expression in normal versus tumor tissue (log2 FC = −1.641, t-test p < 0.001).
This table shows molecular features associated with TEK in patient tissues and cancer cell lines. In patient samples, TEK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
